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patients treated with angioplasty for symptomatic
peripheral arterial disease
Corey A. Kalbaugh, MS, Spence M. Taylor, MD, Dawn W. Blackhurst, DrPH,
Matthew B. Dellinger, BS, E. Annie Trent, BS, and Jerry R. Youkey, MD, Greenville, SC
Background: Despite lower reported patency rates than open bypass, percutaneous transluminal angioplasty (PTA) may
result in symptom relief, limb salvage, maintenance of ambulation and independent living, and overall improved quality
of life. The goal of this study was to prospectively assess quality of life and functional outcomes after angioplasty and
stenting in patients with chronic leg ischemia.
Methods: From August to December 2002, 84 patients with 118 chronically ischemic limbs underwent PTA with or
without stenting as part of an ongoing prospective project performed to examine management of symptomatic peripheral
arterial disease. All patients completed a preprocedure health questionnaire (Short Form 36) to provide adequate baseline
data. Each patient was followed up every 3months after treatment for 1 year to determine traditional outcomes of arterial
patency, limb salvage, survival and amputation-free survival, and functional outcomes assessed according to improvement
in quality of life, maintenance of ambulatory status, and maintenance of independent living status. The entire cohort was
analyzed, as were subgroups of patients with lifestyle-limiting claudication and those with critical limb ischemia.
Outcomes were analyzed by using Kaplan-Meier life-table analysis, the log-rank test for survival curves, and the
one-sample t test. A Cox proportional hazard model was used to determine whether presentation and level of disease were
independent predictors of outcome.
Results:Of the 84 patients, 54 (64.3%) were treated for claudication (34 aortoiliac occlusive disease and 20 infrainguinal
disease), and 30 (35.7%) were treated for critical limb ischemia (11 aortoiliac occlusive disease and 19 infrainguinal
disease). One-year results for the 54 patients with claudication were as follows: primary patency, 78.5%; limb salvage,
100%; amputation-free survival, 96.3%; survival, 96.3%; maintenance of ambulation status, 100%; and maintenance of
independence, 100%. There was statistical improvement in all physical function categories, including physical function
(29.4 8.9 vs 37.1 11.3; P< .0001), role-physical (32.5 11.3 vs 39.5 13.0; P .0001), bodily pain (35.8 8.5
vs 42.9 10.9; P< .0001), and aggregate physical scoring (31.1 9.7 vs 38.1 11.5; P< .0001). One-year results for
the 30 patients with critical limb ischemia were as follows: primary patency, 35.2%; limb salvage, 77.2%; amputation-free
survival, 50.0%; survival, 60.0%; maintenance of ambulation status, 75.8%; and maintenance of independence, 92.8%.
There was statistical improvement in bodily pain resolution (35.3  12.0 vs 46.6  12.0; P  .0009). Cox models with
hazard ratios (HRs) revealed that presentation was a significant predictor for outcomes of primary patency (HR, 4.2; P
.0002), secondary patency (HR, 6.0; P < .0001), limb salvage (HR, 20.2; P  .0047), survival (HR, 10.9; P  .0002),
and amputation-free survival (HR, 11.2; P < .0001). Conversely, the level of disease was predictive of outcome only for
primary patency (HR, 1.8; P  .00289).
Conclusions:Despite inferior reconstruction patency rates when compared with the historical results of open bypass, PTA
provides excellent functional outcomes with good patient satisfaction, especially for treating claudication. These findings
support a more liberal use of PTA intervention for patients with vasculogenic claudication. (J Vasc Surg 2006;44:
296-303.)Attitudes regarding the appropriate treatment of pe-
ripheral atherosclerosis have evolved significantly over the
past 20 years. Originally, vascular surgeons relegated angio-
plasty to the radiologists and considered the therapy second
rate because of intrinsic technical limitations and inferior
patency rates when compared with open surgery. As vascu-
lar surgeons have learned endovascular skills, they have
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296become agreeable to peripheral angioplasty as a tool to treat
lower extremity ischemia. Similarly, attitudes regarding the
treatment of chronic lower extremity ischemia have
changed as well. Stimulated by recently published studies
demonstrating the functional benefit of early intervention
on claudicants1 and the occasional futility of treating des-
perate cases of limb salvage,2 our treatment tendencies have
evolved accordingly. Arguably, today our attitude toward
the aggressive interventional treatment of claudication is at
an all-time peak, and the primary interventional treatment
of choice is percutaneous transluminal angioplasty (PTA).
It has long been accepted that results after PTA yield
inferior patency but lower perioperative mortality when
compared with open bypass.3 Fueled by our changing
attitudes, we have adopted a policy of liberal PTA use in
claudicants with observations that it is initially beneficial in
wn b
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tion has forced us to re-examine our end points of success.
With increasing acceptance, most now appreciate that im-
proved quality of life, enhanced patient satisfaction, main-
tenance of ambulation, and maintenance of independence
supersede arterial reconstruction patency as the most im-
portant determinants of success. Despite this, there is a
paucity of objective data to support this belief. The purpose
of this prospective study, therefore, was to objectively assess
quality of life and functional outcomes after PTA in patients
with lower extremity peripheral arterial disease (PAD).
METHODS
From August 1, 2002, to December 31, 2002, all
patients participating in the LEGS (Lower Extremity Grad-
ing System) prospective study protocol at our institution
who underwent PTA for the treatment of symptomatic
lower extremity PAD were assessed for quality-of-life and
functional outcome changes as a result of their interven-
tion. We identified 84 patients and 118 limbs treated by
PTA for claudication (54 [64.3%] patients and 78 [66.1%]
limbs) or for critical limb ischemia (30 [35.7%] patients and
40 [33.9%] limbs). Interventions included 44 femoral-
popliteal or tibial angioplasty procedures (11 with stent)
Fig. Percutaneous transluminal angioplasty was offere
symptomatic peripheral arterial disease of the lower extre
the LEGS (Lower Extremity Grading System) score, shoand 74 aortoiliac angioplasty procedures (73 with stent).The 44 infrainguinal interventions consisted of 29 SFA, 3
popliteal, 5 tibial, and 7 multilevel angioplasties.
The LEGS treatment algorithm (Fig) was used to direct
therapy for all patients presenting for the invasive manage-
ment of symptomatic lower extremity PAD during this
time.4 This study represents a population of patients who
had experienced medical management failure and met clin-
ical indications for intervention. Medical management typ-
ically consists of smoking cessation counseling and a 3- to
12-month trial of both supervised and unsupervised walk-
ing exercise. The use of this treatment algorithm, which
was studied under institutional review board approval with
the results of treatment being previously reported,5,6 typi-
cally designated claudicants and patients with critical limb
ischemia and short segment arterial stenoses to PTA. This
study population (mean age, 64.5  11.2 years; median,
65.5 years; range, 38-84 years) consisted of 56 men and 28
women (74 white and 10 black) who had the following
comorbidities: diabetes mellitus (44.1%), a history of ciga-
rette smoking (85.7%), and severe coronary artery disease
(16.7%), as assessed by the LEGS score outcomes study.5
Each patient was assessed for baseline ambulatory sta-
tus and resident living status. Also, each patient completed
an Short Form 36 (SF-36) health assessment survey. For
patients who presented with operative indications for
s on the basis of an aggregate score of 10 to 19 by using
elow.d to
mitiethe purpose of the study, ambulatory status was classified as
ritical
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latory/transfer only, or nonambulatory/bedridden. Living
status was classified as independent at home, living in an
assisted-living facility (a communal facility where indepen-
dence for its residents is allowed but meals are provided and
assistance is given as needed), or living in a nursing home
(defined as a facility where all daily functions are assisted by
personnel at the institution).
The SF-36 health assessment survey offers patients a
chance to make an informal estimate of their own overall
health andwell-being. The surveymeasures 10 areas of health:
physical function, role-physical, bodily pain, general health,
vitality, social function, role-emotional, mental health, an
aggregate physical health score, and an aggregate mental
health score.7
Patients were followed up every 3 months for 1 year.
The SF-36 survey was repeated at 6 and 12 months. Out-
come measures included arterial reconstruction patency
(determined by thrombosis of the treated vessel as detected
at physical examination and confirmed at duplex ultrasound
scanning or by deterioration to preinterventional ankle-
brachial index), limb salvage, mortality and amputation-
free survival rates, maintenance of ambulatory status (a
change in ambulation status was defined as a deleterious
change in the ambulation category listed previously), main-
tenance of independent living status (a change in indepen-
dent living status was defined as a deleterious change in the
independent living category listed previously), and a
change in the SF-36 health survey score.
Arterial reconstruction patency, limb salvage, survival,
amputation-free survival, maintenance of ambulation, and
maintenance of independence were measured by using
Kaplan-Meier life-table analysis, and associated survival
curves were compared by using the log-rank test. Prepro-
cedure SF-36 scores were compared with postprocedure
SF-36 scores by using the one-sample t test. A Cox propor-
tional hazard model was used, when appropriate, to mea-





6 mo 95% CI 1 y 95% CI 6 mo
Overall 118 73.2 64.9-81.5 64.7 55.7-73.6 87.7
Claudication 78 87.9 80.5-95.3 78.5 69.1-87.8 97.3
CLI 40 42.3 25.4-59.1 35.2 18.6-51.8 67.9
CI, Confidence interval; CLI, critical limb ischemia.





6 mo 95% CI 1 y
Overall 84 83.3 75.4-91.3 83.3
Claudication 54 96.3 91.3-100.0 96.3
CLI 30 60.0 42.5-77.5 60.0
PTA,Percutaneous transluminal angioplasty; CI, confidence interval; CLI, csure the ability of a specific variable to predict outcome.RESULTS
One-year follow-up was completed for all 118 limbs
treated. Primary patency, secondary patency, and limb sal-
vage are shown in Table I for the entire cohort and segre-
gated by treatment indication (claudication or critical limb
ischemia). Of the 118 limbs treated, there were no early
(30 days; in-hospital) deaths or major complications;
however, there were 11 early primary failures. Four of these
failed PTAs were salvaged by additional PTA for secondary
patency. Primary and secondary patency rates were 73.2%
and 87.7%, respectively, at 6 months and 64.7% and 83.8%
at 1 year. As can be seen in Table I, patients with critical
limb ischemia had statistically significantly inferior patency
as compared with patients with claudication. Seven patients
lost a total of eight limbs at 1 year for a Kaplan-Meier limb
salvage rate of 93.4%. There was no limb loss in the claudi-
cation group—a difference that was statistically significant.
Three of the eight patients requiring major limb amputa-
tion were able to salvage ambulation with the use of a
prosthetic limb.
Survival and amputation-free survival for the entire
series and by indication for treatment are shown in Table II.
Patients experienced an 81.4% and a 79.7% amputation-
free survival rate at 6 months and 1 year, respectively. At 1
year, 14 patients, 12 in the critical limb ischemia group,
died, for a Kaplan-Meier survival rate of 83.3%. Survival and
amputation-free survival were significantly lower in the
critical limb ischemia group.
Maintenance of ambulatory status and maintenance of
living status for the entire series and by indication for
treatment are shown in Table III. Of the 84 patients, only
5 patients experienced a decline in their preprocedure
ambulatory ability at 6 months, and only 6 patients experi-
enced a decline at 1 year, for rates of 93.7% and 92.3%,
respectively. There were no nursing home patients before
the procedure, and there were only two patients who lived
ondary patency (%) Limb salvage (%)
5% CI 1 y 95% CI 6 mo 95% CI 1 y 95% CI
6-93.7 83.8 77.0-90.7 95.4 91.5-99.3 93.4 88.7-98.1
7-100.0 94.6 89.5-99.7 100 — 100 —
6-83.1 61.1 44.7-77.5 85.0 72.6-97.3 77.2 62.0-92.4
nd 1 year
Amputation-free survival (%)
95% CI 6 mo 95% CI 1 y 95% CI
5.4-91.3 81.4 74.3-88.4 79.7 72.4-86.9
1.3-100.0 96.3 90.0-99.8 96.3 90.0-99.8








4in an assisted living facility at the time of presentation. The
critica
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family members. Only three patients experienced a change
in preprocedure living status. Two of these patients were
admitted to a nursing home shortly after discharge from the
hospital after successful endovascular procedures, and a
third was admitted to a nursing home after bilateral above-
knee amputations. Each of these three patients was in the
group with critical limb ischemia. Kaplan-Meier life-table
analysis revealed a 6-month maintenance-of-living-status
rate of 97.5% at 6 months and 96.1% at 1 year. All patients
in the claudication group maintained their ambulatory
status and their independent living status at 1 year, com-
pared with 75.8% and 87.3%, respectively, for the critical
limb ischemia group, a difference that was statistically sig-
nificant.
When looking at data by the level of disease treated,
aortoiliac disease fared better than infrainguinal disease
overall. The primary and secondary patency rates at 1 year
for aortoiliac intervention vs infrainguinal intervention
were 67.6% and 84.5% vs 45.6% and 78.2%, respectively.
Limb salvage and amputation-free survival rates at 1 year
for aortoiliac intervention vs infrainguinal intervention
were 97% and 88.9% vs 85.4% and 64.1%, respectively.
Although these differences were both statistically and clin-
ically significant, the indication for intervention (claudica-
tion vs critical limb ischemia) was more predictive of even-
tual outcome than the level of disease treated. With a Cox
proportional hazard model, the level of disease was found
to be a statistically significant independent predictor of
outcome for only one parameter: primary patency (hazard
ratio [HR], 1.8; P .0289). In contrast, the indication for
intervention was found to be a statistically significant inde-
pendent predictor of outcome for death (HR, 10.9; P 
.002), amputation-free survival (HR, 11.2; P  .0001),
primary patency (HR, 4.2; P  .002), secondary patency
(HR, 6.0; P  .0001), and limb salvage (HR, 20.2; P 
.0047). When considering the level of disease treated and
the indication for the procedure, the best performers were
claudicants receiving PTA of the aortoiliac arteries (primary
patency, 78.9%; secondary patency, 92.3%; limb salvage,
100%; survival, 97.1%; amputation-free survival, 97.1%;
maintenance of ambulation, 100%; and maintenance of
independent living status, 100%). The worst performers
were patients with critical limb ischemia receiving PTA of
the infrainguinal vessels (primary patency, 23.1%; second-
ary patency, 56%; limb salvage, 65.6%; survival, 52.6%;





6 mo 95% CI 1 y
Overall 84 97.3 88.3-99.1 92.3
Claudication 54 100 — 100
CLI 30 80.8 65.5-96.2 75.8
PTA, Percutaneous transluminal angioplasty; CI, confidence interval; CLI,amputation-free survival, 42.1%; maintenance of ambula-tion, 69.2%; and maintenance of independent living status,
93.8%).
A total of 70 patients received a pretreatment,
6-month, and 1-year SF-36 survey. When considering the
entire group, there was statistically significant improvement
in all categories except general health and role-emotional at
6 months. At 1 year, all physical health categories showed
statistically significant improvement, but no emotional or
mental health category was statistically improved. A com-
parison of pretreatment, 6-month, and 1-year SF-36 health
assessment surveys for patients with claudication vs critical
limb ischemia is shown in Table IV. Patients with claudica-
tion significantly improved all outcome measures with the
exception of general health at 6 months and general health,
vitality, role-emotional, mental health, and aggregate men-
tal health at 1 year. In contrast, there was no statistically
significant improvement from pretreatment SF-36 assess-
ment in patients with critical limb ischemia at 1 year in any
category except bodily pain and role-emotional. Likewise, a
comparison of pretreatment, 6-month, and 1-year SF-36
health assessment surveys for patients with aortoiliac occlu-
sive disease vs infrainguinal disease is shown in Table V.
Patients with aortoiliac occlusive disease significantly im-
proved all outcomemeasures at 1 year with the exception of
general health, role-emotional, mental health, and aggre-
gate mental health. Patients with infrainguinal disease im-
proved at 1 year in physical function, bodily pain, and
aggregate physical health.
DISCUSSION
In the hands of appropriately trained proceduralists,
PTA has become a reliable technical alternative to surgical
bypass in many cases. Early technical success for most
lesions treated exceeds 90%, and periprocedural morbidity
is low.8 However, most vascular surgeons consider inter-
mediate and long-term results to be inferior to those with
open bypass. Although this may be true when arterial
reconstruction patency is measured, it may not be the case
when functional outcomes (such as maintenance of inde-
pendence) are measured or when subjective quality-of-life
outcomes (such as patient satisfaction) are used. Objective
data in the latter category are sparse.
The purpose of this study was to investigate functional
and quality-of-life outcomes in a group of patients under-
going endovascular treatment for claudication and critical
limb ischemia. To do this, we prospectively followed up 84
hs and 1 year
Independence maintenance (%)
5% CI 6 mo 95% CI 1 y 95% CI
.4-98.2 97.5 94.1-100.0 96.1 91.8-100.0
— 100 — 100 —





58patients who underwent PTA for symptomatic lower ex-
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ischemia. In addition to the traditional measures of pa-
tency, survival, and limb salvage, we assessed maintenance





Claudication (n  52)
Physical function 29.4  8.9 37.
Role-physical 32.5  11.3 38.
Bodily pain 35.8  8.5 44.
General health 41.3  11.5 42.
Vitality 42.7  13.1 49.
Social function 39.8  15.2 45.
Role-emotional 40.8  16.9 46.
Mental health 55  15.1 51.
Agg physical 31.1  9.7 37.
Agg mental 49.0  15.2 53.
Critical limb ischemia (n  18)
Physical function 27.2  10.3 29.
Role-physical 30.2  14.0 33.
Bodily pain 35.3  12.0 42.
General health 36.6  9.2 36.
Vitality 41.1  13.2 44.
Social function 35.9  16.0 39.
Role-emotional 42.9  16.5 40.
Mental health 42.8  13.1 46.
Agg physical 27.6  13.9 30.
Agg mental 49.0  11.6 49.
Agg, Aggregate.
*Statistically significant (P .05).





Aortoiliac (n  42)
Physical function 29.4  8.9 38.8  1
Role-physical 32.5  11.3 39.3  1
Bodily pain 35.8  9.1 44.2  1
General health 40.7  11.5 42.2  1
Vitality 40.2  13.6 49.9  1
Social function 38.0  15.3 45.4  1
Role-emotional 40.7  16.7 46.9  1
Mental health 44.7  14.7 51.2  1
Agg physical 31.0  10.4 37.7  1
Agg mental 47.6  14.8 53.8  1
Infrainguinal (n  28)
Physical function 28.1  9.8 30.3  1
Role physical 31.1  13.1 35.1  1
Bodily pain 35.4  10.0 42.8  1
General health 39.3  10.6 38.8  1
Vitality 45.4  11.7 46.2  1
Social function 39.9  15.7 42.4  1
Role-emotional 42.3  17.1 41.2  1
Mental health 45.0  14.7 48.0  1
Agg physical 28.9  11.9 32.1  1
Agg mental 51.0  13.5 51.5  1
Agg, Aggregate.
*Statistically significant (P .05).of ambulatory status, maintenance of independent livingstatus, and subjective well-being by using the SF-36 health
assessment survey before and after intervention. We were
able to achieve acceptable technical success, including an
nd after endovascular intervention for claudication and
ow-up 1-y follow-up
Difference
at 1 y P value
3.1* 37.1  11.3 9.2 .0001*
1.9* 39.5  13.0 7.0 .0001*
0.8* 42.9  10.9 7.2 .0001*
1.4 41.2  11.9 0.2 .91
2.6* 45.7  15.0 3.0 .18
1.2* 46.9  12.9 7.1 .0015*
2.4* 43.0  15.6 2.2 .38
1.3* 48.8  14.8 3.3 .07
3.5* 38.1  11.5 7.0 .0001*
.8* 50.8  13.2 1.8 .38
3.3 30.1  14.3 2.9 .30
4.3 30.9  13.3 0.7 .85
1.5* 46.6  12.0 11.2 .0009*
.7 38.0  10.7 1.4 .57
2.0 42.9  14.9 1.7 .56
5.3 40.5  14.1 4.5 .19
8.2 32.8  18.8 10.2 .042*
2.6 40.3  15.6 2.5 .51
2.5 32.1  13.4 4.6 .17
2.1 43.9  15.3 5.0 .15
d after endovascular intervention for aortoiliac disease
1-y follow-up
Difference
at 1 y P value
37.1  11.3 7.7 .0001*
39.2  12.8 6.7 .0005*
46.0  9.4 10.2 .0001*
39.6  11.7 1.1 .54
45.9  114.0 5.7 .0180*
46.0  12.3 8.0 .0008*
42.6  15.5 1.8 .59
48.0  13.5 3.3 .14
37.7  12.2 6.7 .0002*
50.4  12.0 2.8 .28
33.4  13.3 5.3 .0195*
335.4  13.4 4.3 .14
41.5  11.8 6.1 .0161*
42.5  9.6 3.2 .10
45.1  14.8 0.3 .91
45.3  12.7 5.5 .08
39.2  17.3 3.1 .31
46.0  15.0 1.0 .69
35.3  11.7 6.3 .0210*
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rate, and nearly an 80% amputation-free survival rate—
findings comparable to those of many previously reported
studies.3,8 Findings unique to this study included a notable
1-year maintenance-of-ambulation rate of 92.3% and a
maintenance-of-independent-living-status rate of 96.1%.
Also, SF-36 health assessment significantly improved for
the overall series in nearly every category at 6 months and
for nearly all physical status measures at 1 year. General
health assessment and most of the emotional assessment
categories were unchanged at 1 year for the overall group.
As with traditional outcomes (patency and limb sal-
vage), quality-of-life assessment was significantly affected
by the indication for treatment. Claudicants consistently
outperformed patients undergoing treatment for critical
limb ischemia in nearly every SF-36 parameter measured.
These differences persisted regardless of the arterial level
treated (infrainguinal vs aortoiliac). However, despite this,
patients with critical limb ischemia were able to maintain
both their ambulatory ability and independent living status;
more than 75% of patients were both ambulatory and
independent at 1 year. Further examination showed that
quality-of-life gains as measured by the SF-36 survey for
claudicants at 6 months deteriorated in several categories at
1 year. This can perhaps be explained by a corresponding
loss of primary patency in the same time interval.
It can be concluded that although claudicants feel
better and feel better about their overall health than pa-
tients with critical limb ischemia, PTA achieves very good
functional outcomes for both groups of patients at 1 year.
Despite a disappointing and dismal primary patency rate of
35% in patients with critical limb ischemia, PTA seems to be
very beneficial for measuring functional parameters such as
maintenance of ambulation and independence. Although it
would be interesting to measure these parameters against
untreated controls (a conceded limitation of this study), it
is still reasonable to conclude that, on the basis of preserv-
ing functionality at least in the short term, PTA is worth-
while in patients, regardless of presentation, who are ame-
nable to this therapy.
It is important to remember that patients treated in this
series were assigned treatment by the LEGS score protocol.
This protocol tends to designate claudicants and functionally/
medically high-risk patients to PTA.4 We believe that this
explains the survey results of the SF-36 self-assessment for the
critical limb ischemia group. The LEGS treatment algorithm
generally selects sicker patients for PTA, using the rationale
that good-risk patients live longer and thus need the benefit of
more durable open procedures. It also uses the corollary that
poorer-risk patients do not tolerate open surgery as well, do
not need the durability of open operations, and thus are better
treated with PTA. It is reasonable, therefore, to postulate that
had we taken better-risk limb salvage candidates, the SF-36
data may have been different.
Irrespective of this, however, the data for patients with
claudication are interesting and seem to support an argu-
ment for a more aggressive approach for patients with
non–limb-threatening PAD. These findings are similar tothose of Feinglass et al,1 who performed a functional out-
comes assessment of more than 500 patients with claudica-
tion, 104 of whom underwent arterial intervention. They
demonstrated considerable improvement in functional out-
come for these patients as compared with a series of
matched and unmatched controls who underwent medical
management and concluded that intervention shows a
measurable benefit for patients with claudication. Although
the mainstay of therapy for claudication continues to be
smoking cessation and monitored exercise (walking), this
treatment modality has documented shortcomings. If one
were to critically assess the literature regarding the nonin-
terventional treatment of claudication, one could conclude
that success, defined as the ability to walk and perform the
tasks of daily living without leg pain, is possible in only one
third of patients treated. Substance abuse data regarding
cigarette smoking cessation published in the 1980s suggest
that only one third of patients with smoking-related dis-
eases will ever completely quit smoking cigarettes.9 Like-
wise, literature from Europe has suggested that only one
third of patients are both physically able and mentally
willing to participate in a meaningful exercise program to
correct their claudication.10 Considering this, noninterven-
tional therapy leaves up to two thirds of its sufferers without
hope for a successful outcome.
Classic teaching would argue that the relatively benign
natural history of claudication does not justify intervention.
Studies also show that the benefits after revascularization
when exercise performance is measured are more subjective
than objective. In a study by Gardner and Killewich,11 it was
not possible to demonstrate improved objective performance
in the form of improved walking distance after revasculariza-
tion, despite patients’ subjective belief that they were walking
farther than before their intervention. They concluded from
their findings that the benefits of revascularization are often
subjective and that exercise training after intervention is nec-
essary to accommodate the chronic muscle deconditioning
that occurs with chronic PAD.Other studies have shown that
the subjective benefits of PTA are often lost by 1 year when
compared with cohorts subjected to supervised exercise and
smoking cessation only.12,13 Clearly this highlights the most
glaring pitfall of our study: a follow-up of only 1 year. It would
be interesting to retest the self health assessment in our study
population at 2 years. Another possible shortcoming to our
study is the method chosen to measure health-related quality
of life. The SF-36 is considered a generic health-related qual-
ity-of-life measure. Reports from Europe have suggested that
disease-specific quality-of-life questionnaires designed for pa-
tients with PAD may provide more reliable quality-of-life
data.14,15 However, a recent report by Izquierdo-Porrera
et al16 suggests that the SF-36 questionnaire is as effective as
disease-specific questionnaires. Our study used only the ge-
neric SF-36. Despite these shortcomings, patients treated in
this prospective trial generally believed that they benefited
from interventional therapy. These data incrementally add to
the growing body of evidence rationalizing a more aggressive
approach for claudication.
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tion with critical limb ischemia. Although PTA seemed to
preserve the ability to walk and maintain independence, it did
not seem to improve overall quality-of-life. In other data
published from our institution, the postoperative functional
outcome was often predetermined by the functional status of
the patient at presentation.17 Elderly patients with preopera-
tive ambulatory impairment, dementia, and end-stage renal
disease often achieved very little improvement in their func-
tional performance after objectively successful revasculariza-
tion, regardless of whether the treatment was PTA or open
bypass.On the basis of this experience, it has been our opinion
that we overtreat some patients with critical limb ischemia. If
one were to take a skeptical perspective, the data in this report
show that PTA resulted in amputation-free survival in only
half the cases and provided no improvement in patient health
self-assessment. These outcomes are far from an endorsement
of PTA for the treatment of patients with critical limb isch-
emia. All things considered, the aggregate findings of this
report have done little to change our original opinion.Clearly,
more prospective research in this area is needed to determine
which patients will derive a functional benefit from interven-
tion and which will not.
In summary, technological advancements in the percuta-
neous treatment of PAD have enabled proceduralists to suc-
cessfully treat more complex arterial lesions. Despite docu-
mented limitations in the technical parameter of arterial
patency, excellent functional outcomes with good quality-of-
life assessment are attainablewithPTA.This is particularly true
in patients with claudication. On the grounds of improving
functionality, our findings support a growing body of litera-
ture advocating a more aggressive percutaneous interven-
tional approach to patients with vasculogenic claudication.
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Dr. Robinson: This analysis involves a subgroup of 84 pa-
tients from a previous study who underwent angioplasty forand quality of life was assessed using the SF 36. Patients generally
do well, keep their limbs, remain independent and ambulatory,
have an improved quality of life, and are generally happy. Impor-
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Volume 44, Number 2 Kalbaugh et al 303tantly, there were no amputations among the 78 limbs treated for
claudication, and a statistically significant improvement in SF-36
measures in all physical function categories. Consequently, the
authors suggest a more liberal use of PTA interventions for patients
with claudication.
However, others have had difficulty showing improvement in
SF-36 scores among vascular patients with any intervention. And
still other survey-tools appear more discriminating in detecting
levels of ischemia and degrees of patient improvement. So for a
sicker patient with more severe disease, even a limited outcome
may be positive and just being able to stand to transfer on one leg
may make a difference. My first question for the authors is about
the limitations of the SF-36 versus more disease-specific question-
naires: Is the SF-36 specific enough and the right “tool” to use to
measure outcomes?
Secondly, one year follow-up gives us little more than a
‘snapshot’, and there is no comparative group. Furthermore, exer-
cise and best medical therapy can measurably improve walking
distance and quality of life for many claudicants. Could you clarify
if all claudicants were relegated to an intervention, or whether
outcomes exist for comparable groups receiving best medical man-
agement alone? Is medical management for claudication passé and
should be abandoned?
Many authors, including our group, have used alternative
methods of assessing patient outcomes to accomplish even better
understanding of “cost-effective” therapy using Markov modeling
to calculate Quality-Adjusted Life Years (QALYs). This would
seem to be ideally suited to the authors’ population. Could the
authors comment and would they consider the application of such
an analysis in a future report?
One last comment. Rapidly developing technology not widely
available when this study was initiated proliferates and nearly
outruns our ability to acquire and analyze meaningful data. None-
theless, modern and sophisticated assessment must include both
delineation of patient function and an analysis of outcomes. I
congratulate the authors on these important efforts and look
forward to their future contributions.
Dr. Tayor: Thanks very much for those comments and ques-
tions. The SF-36 form is an outcomes tool. It is not a perfect tool.
It is one that has become used more widespread than many others,
and I think it is—one needs to caution trying to pick out an
outcomes assessment tool that is tailor made to your patient
population in order to more or less achieve the results that you
wanted to achieve.
In terms of answering that question with theMarkhoff model,
our goal in all of this was to try to keep it very simple. We are
basically blue collar practicing surgeons that have an interest in
trying to figure out what works and what doesn’t work. I mean can
the patient still walk at the end of the procedure and a year later, is
the patient in a nursing home, can the patient stand to dress. Theseto me are things that we as vascular surgeons can understand and
adapt for our patients more so than even a Markhoff model, but I
don’t dispel that we would not have an ideal population for this.
I think the question regarding the medical management of
claudication is intriguing. Be mindful that the LEGS trial, all of
these patients basically hadmedical management first and they only
were enrolled in the LEGS trial after we decided that medical
management was no longer an option and you had made the
decision that you were going to treat this patient with some type of
intervention and selected the treatment for you. All of these
patients had failed medical management before they came to the
trial. The cold hard truth about medical management is—and we
pointed out in the literature—if you really take a pessimistic view of
medical management of claudication, there are multiple studies
that show from the addiction literature that only about a third of
patients that smoke, even though they have a life-threatening
illness, are going to quit smoking. There are studies from Europe
that show that functionality and just patient obstinate alone will
keep people from entering an exercise program in as many as
two-thirds of cases, so if you are a real pessimist you can say that our
best expectation of treating people with medical management is
going to be about a third of patients. Again, that is a very pessimis-
tic view. I’m not advocating that you don’t try, because I think it is
probably the right thing to do but I believe that the things that we
measure from the perspective of claudication is probably no differ-
ent than maybe—and again my opinion—somebody that is having
a knee replacement for an arthritis. These are old people that
basically have bad joints and they can’t walk and they have tried
everything they can do in terms of—is it that much different than
if you are going to treat an SFA angioplasty? It’s clearly a different
disease than what we see with limb-threatening ischemia. I think as
a followup and sort of as a whole digested, to digest everything we
have heard this morning, the striking feature of this study and all
the other studies is critical limb ischemia is a radically different
disease than claudication. It is a radically different disease. It is
manifest in the same disease process in terms of atherosclerosis,
but, as Dan Rush pointed out, critical limb ischemia, in our
conversation this morning, is a systemic disease. We have not
solved—critical limb ischemia is what we talked about on Friday.
We have not solved that problem. That’s a terrible problem, but
claudication, if your mindset is grouped and the claudication
patients are like critical limb ischemia patients, I think you may be
denying some people some treatment that you could possibly help.
Sort of a radical view I think.
It is a moving target. All this is a moving target, the technical
portion of it. In our practice we tend to keep up with the technical
advances in endovascular as well as anybody. I have some really
talented guys, partners, that work with us and work with me and
I’m very blessed to have that, but it is an issue.
